Conferences - Results from #8360

GU Cancers Symposium 2014 - Evaluating the safety of abiraterone acetate and docetaxel administered in combination in patients with metastatic castration-resistant prostate cancer - Poster February 4, 2014

GU Cancers Symposium 2014 - An indirect treatment comparison and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer post-chemotherapy - Poster February 4, 2014

GU Cancers Symposium 2014 - Poster: Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with mCRPC... February 4, 2014

GU Cancers Symposium 2014 - Poster: Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study February 4, 2014

GU Cancers Symposium 2014 - Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients - Poster February 4, 2014

GU Cancers Symposium 2014 - CCP score and risk stratification for prostate cancer patients at biopsy - Poster February 4, 2014

GU Cancers Symposium 2014 - NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer - Poster February 4, 2014

GU Cancers Symposium 2014 - Association of alkaline phosphatase with clinical outcomes in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: Results from COU-AA-302 - Poster February 4, 2014

GU Cancers Symposium 2014 - Model-based investigation of the interplay between abiraterone exposure, prostate-specific antigen kinetics, and overall survival in castration-resistant prostate cancer patients - Poster February 4, 2014

GU Cancers Symposium 2014 - Optimal targeting of the PD-1/PDL-1 pathway in metastatic kidney cancer - Session Highlights February 4, 2014

GU Cancers Symposium 2014 - Translating genomics into better cancer care - Session Highlights February 4, 2014

GU Cancers Symposium 2014 - Prognosis, prediction, and update from the International Metastatic Renal Cell Carcinoma Database Consortium - Session Highlights February 4, 2014

GU Cancers Symposium 2014 - BAP1 and PBRM1 in renal cancer - Session Highlights February 4, 2014

GU Cancers Symposium 2014 - Comprehensive molecular characteristics of clear-cell renal cell carcinoma: An update from the CGA Research Network - Session Highlights February 4, 2014

GU Cancers Symposium 2014 - A decade in review: Renal cancer - Session Highlights February 4, 2014

GU Cancers Symposium 2014 - The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in metastatic renal cell carcinoma patients previously treated with first line targeted therapy - Session Highlights February 4, 2014

GU Cancers Symposium 2014 - Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma - Session Highlights February 3, 2014

GU Cancers Symposium 2014 - Results of the MARS study on the management of antiangiogenics’ renovascular safety in renal cell carcinoma - Session Highlights February 3, 2014

Page 419 of 465

email news signup